Galectin Therapeutics Inc

NASDAQ:GALT   3:59:54 PM EDT
2.61
-0.09 (-3.33%)
Products, Regulatory

Galectin Therapeutics Announces Positive Top-Line Results From Phase 1B Trial Extension Of Belapectin In Combination With Keytruda®

Published: 07/09/2021 12:25 GMT
Galectin Therapeutics Inc (GALT) - Galectin Therapeutics Announces Positive Top-line Results From a Phase 1b Clinical Trial Extension of Belapectin in Combination With Keytruda® in Advanced Metastatic Melanoma and Head and Neck Cancer.
Galectin Therapeutics Inc - Combination of Belapectin and Pembrolizumab Was Well Tolerated and Appeared Safe.
Galectin Therapeutics Inc - There Were No Grade 3 Or Adverse Events.